Epidemiology and Surveillance

Split Viewer

Public Health Weekly Report 2021; 14(20): 1314-1325

Published online May 13, 2021

© The Korea Disease Control and Prevention Agency

The clinical importance of office BP 130/80 mmHg in resistant hypertension

Lee Chan Joo1, Park Sungha1, Lee Joung-Won2, Lee Seung Hee2, Kim Won-Ho2

1Division of Cardiology, Severance Cardiovascular Hospital and Integrative Research Center for Cerebrovascular and Cardiovascular diseases, Yonsei University College of Medicine
2Division of Cardiovascular Disease Research, Department of Chronic Disease Convergence Research, National Institute of Health (NIH), Korea Disease Control and Prevention Agency (KDCA)

Resistant hypertension has a high risk of end-stage renal disease, cardiovascular disease, and death, so it is important to detect resistant hypertension properly and actively control blood pressure (BP). BP can be diagnosed based on office blood pressure, but, when the readings are inaccurate due to certain environments, many patients are classified as white-coat uncontrolled hypertension or masked uncontrolled hypertension with ambulatory BP monitoring. Therefore, it is recommended to use ‘out-of-office’ BP monitoring, such as an active blood pressure test, to determine an appropriate treatment policy for resistant hypertension. Still, this convention is not fully utilized in clinical practice. The objective of this study was to compare the diagnostic accuracy of office BP thresholds of 140/90 and 130/80 mmHg to correctly identify uncontrolled out-of-office BP in resistant hypertension. As a multicenter study conducted in Korea, the results of 468 patients enrolled in the resistant hypertension cohort were analyzed. Office BP, home BP, and ambulatory BP were measured at baseline. Resistant hypertension was defined as office BP ≥ 130/80 mmHg with three different classes of antihypertensive medications, including thiazide-type/like diuretics or treated hypertension with four or more different classes of antihypertensive medications. Uncontrolled out-of-office BP was defined as daytime BP ≥ 135/85 mmHg and/or home BP ≥ 135/85 mmHg. For the diagnosis of uncontrolled out-of-office BP, the accuracy of an office blood pressure of 140/90 mmHg was 60.9%, but the accuracy of an office blood pressure of 130/80 mmHg was 74.1%. When the office BP threshold was changed from 140/90 mmHg to 130/80 mmHg, the net reclassification index for the diagnosis of BP outside the uncontrolled office was 0.543. When the office BP threshold was lowered, the proportion of patients with masked uncontrolled hypertension that were easily neglected to treat decreased. In conclusion, an office BP of 130/80 mmHg can be more accurately classified as uncontrolled out-of-office BP than as office BP 140/90 mmHg and lowering the office BP threshold can be helpful for controlling BP in resistant hypertension.

Key words Resistant hypertension, Office blood pressure, Out-of-office blood pressure, Hypertension phenotypes

Table 1. Definitions of hypertension phenotypes
CharacteristicsDefinitions
Uncontrolled home BPHome BP ≥ 135/85 mmHg
Uncontrolled daytime BPABPM daytime BP ≥ 135/85 mmHg
Uncontrolled out-of-office BPDaytime BP ≥ 135/85 mmHg and/or
Home BP ≥ 135/85 mmHg
Controlled hypertensionOffice BP < target BP and
Out-of-office BP < target BP
White-coat uncontrolled hypertensionOffice BP ≥ target BP and
Out-of-office BP < target BP
Masked uncontrolled hypertensionOffice BP < target BP and
Out-of-office BP ≥ target BP
Sustained uncontrolled hypertensionOffice BP ≥ target BP and
Out-of-office BP ≥ target BP


Table 2. Baseline characteristics according to status of out-of-office blood pressure
VariablesTotal
(N=468)
Controlled out-of-office BP
(N=111)
Uncontrolled out-of-office BP
(N=357)
p-value*
Age, years60.8±12.961.1±11.860.7±13.20.770
Male, N (%)270 (57.7%)62 (55.9%)208 (58.3%)0.735
Height, cm163.8±9.7163.1±10.4164.1±9.50.366
Weight, kg75.7±15.375.1±17.275.9±14.80.693
Body mass index, kg/m228.0±4.128.0±4.328.0±4.10.949
Current smoker, N (%)72 (15.4%)9 (8.1%)63 (17.6%)0.022
Alcohol drinking, N (%)283 (60.5%)66 (59.5%)217 (60.8%)0.890
Diabetes, N (%)311 (66.5%)75 (67.6%)236 (66.1%)0.865
Dyslipidemia, N (%)467 (99.8%)111 (100.0%)356 (99.7%)1.000
Chronic kidney disease, N (%)31 (6.6%)2 (1.8%)29 (8.1%)0.034
Heart failure, N (%)42 (9.0%)10 (9.0%)32 (9.0%)1.000
Myocardial infarction, N (%)21 (4.5%)6 (5.4%)15 (4.2%)0.785
Angina, N (%)102 (21.8%)30 (27.0%)72 (20.2%)0.162
Stroke, N (%)45 (9.6%)4 (3.6%)41 (11.5%)0.023
Transient ischemic attack, N (%)8 (1.7%)1 (0.9%)7 (2.0%)0.739
Blood urea nitrogen, mg/dL18.5±11.117.8±5.118.8±12.40.222
Creatinine, mg/dL0.9±0.30.9±0.21.0±0.40.001
Glucose, mg/dL117.5±31.2118.5±30.3117.2±31.50.711
Total cholesterol, mg/dL165.7±34.6164.0±38.0166.2±33.50.575
LDL-cholesterol, mg/dL89.9±32.388.7±33.190.3±32.10.669
HDL-cholesterol, mg/dL48.9±11.549.2±11.748.9±11.40.825
Triglyceride, mg/dL141.0 (105.0-191.5)142 (104.0-182.0)141 (105.0-198.5)0.642
Na+, mmol/L141.1±2.6140.6±2.5141.3±2.60.018
K+, mmol/L4.3±0.44.3±0.44.3±0.40.877
Urine albumin creatinine ratio18.5 (8.9-76.5)16.8 (8.1-42.2)20.1 (9.2-83.5)0.094

*Presented by t-test or chi-square test



Table 3. Blood pressure measurement and use of antihypertensive medications according to status of out-of-office blood pressure
VariablesTotal
(N=468)
Controlled out-of-office BP
(N=111)
Uncontrolled out-of-office BP
(N=357)
p-value*
Office SBP140.0±18.2130.6±14.2143.0±18.3<0.001
Office DBP80.0±11.776.5±10.181.1±12.0<0.001
Home SBP129.9±12.5120.1±8.5133.0±11.9<0.001
Home DBP78.9±9.274.0±6.180.4±9.5<0.001
Daytime SBP140.1±17.2122.5±7.2145.6±15.7<0.001
Daytime DBP82.6±10.574.8±5.085.1±10.6<0.001
Thiazide-like461 (98.5%)110 (99.1%)351 (98.3%)0.886
Renin-angiotensin system blocker454 (97.0%)106 (95.5%)348 (97.5%)0.452
Calcium channel blocker458 (97.9%)108 (97.3%)350 (98.0%)0.923
Beta blocker387 (82.7%)97 (87.4%)290 (81.2%)0.176
Alpha blocker37 (7.9%)5 (4.5%)32 (9.0%)0.187
Spironolactone84 (17.9%)30 (27.0%)54 (15.1%)0.007
Minoxidil2 (0.4%)0 (0.0%)2 (0.6%)1.000
Number of medications0.144
368 (14.5%)8 (7.2%)60 (16.8%)
4327 (69.9%)85 (76.6%)242 (67.8%)
562 (13.2%)15 (13.5%)47 (13.2%)
610 (2.1%)3 (2.7%)7 (2.0%)
71 (0.2%)0 (0.0%)1 (0.3%)

*Presented by t-test or chi-square test



Table 4. Cross-tabulation of office blood pressure threshold of 140/90 mmHg and out-of-office blood pressure threshold of 135/85 mmHg
Out-of-office blood pressure
ControlledUncontrolledSubtotal
Office blood pressureControlled79151230
Uncontrolled32206238
Subtotal111357468
Sensitivity71.2%
Specificity57.7%
Accuracy60.9%
Positive predictive value34.3%
Negative predictive value86.6%


Table 5. Cross-tabulation of office blood pressure threshold of 130/80 mmHg and out-of-office blood pressure threshold of 135/85 mmHg
Out-of-office blood pressure
ControlledUncontrolledSubtotal
Office blood pressureControlled445498
Uncontrolled67303370
Subtotal111357468
Sensitivity39.6%
Specificity84.9%
Accuracy74.1%
Positive predictive value44.9%
Negative predictive value81.9%


Table 6. Reclassification tables for uncontrolled out-of-office blood pressure according to change of office blood pressure threshold from 140/90 mmHg to 130/80 mmHg
Out-of-office blood pressureOffice blood pressure
140/90 mmHg
Office blood pressure
130/80 mmHg
Reclassification improvement
Controlled (N=111)Controlled (N=79)aControlled (N=44)-0.152i
Uncontrolled (N=35)e
Uncontrolled (N=32)bControlled (N=0)f
Uncontrolled (N=32)
Uncontrolled (N=357)Controlled (N=151)cControlled (N=54)0.407j
Uncontrolled (N=97)g
Uncontrolled (N=206)dControlled (N=0)h
Uncontrolled (N=206)

i=(f-e)/(a+c); j=(g-h)/(b+d); Net reclassification improvement = i+j = 0.255.



Figure 1. Receiver operating characteristic curve analyses of office systolic (A), diastolic (B) blood pressure for identifying uncontrolled out-of-office blood pressure

Figure 2. Hypertension phenotype according to different office blood pressure
  1. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement From the American Heart Association. Hypertension 2018;72(5):e53-e90.
  2. Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension 2019;73(2):424-431.
    Pubmed KoreaMed CrossRef
  3. Sim JJ, Bhandari SK, Shi J, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int 2015;88(3):622-632.
    Pubmed KoreaMed CrossRef
  4. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011;57(5):898-902.
    Pubmed CrossRef
  5. Cardoso CRL, Salles GC, Salles GF. Prognostic importance of on-treatment clinic and ambulatory blood pressures in resistant hypertension: a cohort study. Hypertension 2020;75(5):1184-1194.
    Pubmed CrossRef
  6. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51(6):1403-1419.
    Pubmed CrossRef
  7. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018;71(19):e127-e248.
    CrossRef

Epidemiology and Surveillance

Public Health Weekly Report 2021; 14(20): 1314-1325

Published online May 13, 2021

Copyright © The Korea Disease Control and Prevention Agency.

The clinical importance of office BP 130/80 mmHg in resistant hypertension

Lee Chan Joo1, Park Sungha1, Lee Joung-Won2, Lee Seung Hee2, Kim Won-Ho2

1Division of Cardiology, Severance Cardiovascular Hospital and Integrative Research Center for Cerebrovascular and Cardiovascular diseases, Yonsei University College of Medicine
2Division of Cardiovascular Disease Research, Department of Chronic Disease Convergence Research, National Institute of Health (NIH), Korea Disease Control and Prevention Agency (KDCA)

Abstract

Resistant hypertension has a high risk of end-stage renal disease, cardiovascular disease, and death, so it is important to detect resistant hypertension properly and actively control blood pressure (BP). BP can be diagnosed based on office blood pressure, but, when the readings are inaccurate due to certain environments, many patients are classified as white-coat uncontrolled hypertension or masked uncontrolled hypertension with ambulatory BP monitoring. Therefore, it is recommended to use ‘out-of-office’ BP monitoring, such as an active blood pressure test, to determine an appropriate treatment policy for resistant hypertension. Still, this convention is not fully utilized in clinical practice. The objective of this study was to compare the diagnostic accuracy of office BP thresholds of 140/90 and 130/80 mmHg to correctly identify uncontrolled out-of-office BP in resistant hypertension. As a multicenter study conducted in Korea, the results of 468 patients enrolled in the resistant hypertension cohort were analyzed. Office BP, home BP, and ambulatory BP were measured at baseline. Resistant hypertension was defined as office BP ≥ 130/80 mmHg with three different classes of antihypertensive medications, including thiazide-type/like diuretics or treated hypertension with four or more different classes of antihypertensive medications. Uncontrolled out-of-office BP was defined as daytime BP ≥ 135/85 mmHg and/or home BP ≥ 135/85 mmHg. For the diagnosis of uncontrolled out-of-office BP, the accuracy of an office blood pressure of 140/90 mmHg was 60.9%, but the accuracy of an office blood pressure of 130/80 mmHg was 74.1%. When the office BP threshold was changed from 140/90 mmHg to 130/80 mmHg, the net reclassification index for the diagnosis of BP outside the uncontrolled office was 0.543. When the office BP threshold was lowered, the proportion of patients with masked uncontrolled hypertension that were easily neglected to treat decreased. In conclusion, an office BP of 130/80 mmHg can be more accurately classified as uncontrolled out-of-office BP than as office BP 140/90 mmHg and lowering the office BP threshold can be helpful for controlling BP in resistant hypertension.

Keywords: Resistant hypertension, Office blood pressure, Out-of-office blood pressure, Hypertension phenotypes

Body

Definitions of hypertension phenotypes
CharacteristicsDefinitions
Uncontrolled home BPHome BP ≥ 135/85 mmHg
Uncontrolled daytime BPABPM daytime BP ≥ 135/85 mmHg
Uncontrolled out-of-office BPDaytime BP ≥ 135/85 mmHg and/or
Home BP ≥ 135/85 mmHg
Controlled hypertensionOffice BP < target BP and
Out-of-office BP < target BP
White-coat uncontrolled hypertensionOffice BP ≥ target BP and
Out-of-office BP < target BP
Masked uncontrolled hypertensionOffice BP < target BP and
Out-of-office BP ≥ target BP
Sustained uncontrolled hypertensionOffice BP ≥ target BP and
Out-of-office BP ≥ target BP


Baseline characteristics according to status of out-of-office blood pressure
VariablesTotal
(N=468)
Controlled out-of-office BP
(N=111)
Uncontrolled out-of-office BP
(N=357)
p-value*
Age, years60.8±12.961.1±11.860.7±13.20.770
Male, N (%)270 (57.7%)62 (55.9%)208 (58.3%)0.735
Height, cm163.8±9.7163.1±10.4164.1±9.50.366
Weight, kg75.7±15.375.1±17.275.9±14.80.693
Body mass index, kg/m228.0±4.128.0±4.328.0±4.10.949
Current smoker, N (%)72 (15.4%)9 (8.1%)63 (17.6%)0.022
Alcohol drinking, N (%)283 (60.5%)66 (59.5%)217 (60.8%)0.890
Diabetes, N (%)311 (66.5%)75 (67.6%)236 (66.1%)0.865
Dyslipidemia, N (%)467 (99.8%)111 (100.0%)356 (99.7%)1.000
Chronic kidney disease, N (%)31 (6.6%)2 (1.8%)29 (8.1%)0.034
Heart failure, N (%)42 (9.0%)10 (9.0%)32 (9.0%)1.000
Myocardial infarction, N (%)21 (4.5%)6 (5.4%)15 (4.2%)0.785
Angina, N (%)102 (21.8%)30 (27.0%)72 (20.2%)0.162
Stroke, N (%)45 (9.6%)4 (3.6%)41 (11.5%)0.023
Transient ischemic attack, N (%)8 (1.7%)1 (0.9%)7 (2.0%)0.739
Blood urea nitrogen, mg/dL18.5±11.117.8±5.118.8±12.40.222
Creatinine, mg/dL0.9±0.30.9±0.21.0±0.40.001
Glucose, mg/dL117.5±31.2118.5±30.3117.2±31.50.711
Total cholesterol, mg/dL165.7±34.6164.0±38.0166.2±33.50.575
LDL-cholesterol, mg/dL89.9±32.388.7±33.190.3±32.10.669
HDL-cholesterol, mg/dL48.9±11.549.2±11.748.9±11.40.825
Triglyceride, mg/dL141.0 (105.0-191.5)142 (104.0-182.0)141 (105.0-198.5)0.642
Na+, mmol/L141.1±2.6140.6±2.5141.3±2.60.018
K+, mmol/L4.3±0.44.3±0.44.3±0.40.877
Urine albumin creatinine ratio18.5 (8.9-76.5)16.8 (8.1-42.2)20.1 (9.2-83.5)0.094

*Presented by t-test or chi-square test.



Blood pressure measurement and use of antihypertensive medications according to status of out-of-office blood pressure
VariablesTotal
(N=468)
Controlled out-of-office BP
(N=111)
Uncontrolled out-of-office BP
(N=357)
p-value*
Office SBP140.0±18.2130.6±14.2143.0±18.3<0.001
Office DBP80.0±11.776.5±10.181.1±12.0<0.001
Home SBP129.9±12.5120.1±8.5133.0±11.9<0.001
Home DBP78.9±9.274.0±6.180.4±9.5<0.001
Daytime SBP140.1±17.2122.5±7.2145.6±15.7<0.001
Daytime DBP82.6±10.574.8±5.085.1±10.6<0.001
Thiazide-like461 (98.5%)110 (99.1%)351 (98.3%)0.886
Renin-angiotensin system blocker454 (97.0%)106 (95.5%)348 (97.5%)0.452
Calcium channel blocker458 (97.9%)108 (97.3%)350 (98.0%)0.923
Beta blocker387 (82.7%)97 (87.4%)290 (81.2%)0.176
Alpha blocker37 (7.9%)5 (4.5%)32 (9.0%)0.187
Spironolactone84 (17.9%)30 (27.0%)54 (15.1%)0.007
Minoxidil2 (0.4%)0 (0.0%)2 (0.6%)1.000
Number of medications0.144
368 (14.5%)8 (7.2%)60 (16.8%)
4327 (69.9%)85 (76.6%)242 (67.8%)
562 (13.2%)15 (13.5%)47 (13.2%)
610 (2.1%)3 (2.7%)7 (2.0%)
71 (0.2%)0 (0.0%)1 (0.3%)

*Presented by t-test or chi-square test.



Cross-tabulation of office blood pressure threshold of 140/90 mmHg and out-of-office blood pressure threshold of 135/85 mmHg
Out-of-office blood pressure
ControlledUncontrolledSubtotal
Office blood pressureControlled79151230
Uncontrolled32206238
Subtotal111357468
Sensitivity71.2%
Specificity57.7%
Accuracy60.9%
Positive predictive value34.3%
Negative predictive value86.6%


Cross-tabulation of office blood pressure threshold of 130/80 mmHg and out-of-office blood pressure threshold of 135/85 mmHg
Out-of-office blood pressure
ControlledUncontrolledSubtotal
Office blood pressureControlled445498
Uncontrolled67303370
Subtotal111357468
Sensitivity39.6%
Specificity84.9%
Accuracy74.1%
Positive predictive value44.9%
Negative predictive value81.9%


Reclassification tables for uncontrolled out-of-office blood pressure according to change of office blood pressure threshold from 140/90 mmHg to 130/80 mmHg
Out-of-office blood pressureOffice blood pressure
140/90 mmHg
Office blood pressure
130/80 mmHg
Reclassification improvement
Controlled (N=111)Controlled (N=79)aControlled (N=44)-0.152i
Uncontrolled (N=35)e
Uncontrolled (N=32)bControlled (N=0)f
Uncontrolled (N=32)
Uncontrolled (N=357)Controlled (N=151)cControlled (N=54)0.407j
Uncontrolled (N=97)g
Uncontrolled (N=206)dControlled (N=0)h
Uncontrolled (N=206)

i=(f-e)/(a+c); j=(g-h)/(b+d); Net reclassification improvement = i+j = 0.255..



Figure 1. Receiver operating characteristic curve analyses of office systolic (A), diastolic (B) blood pressure for identifying uncontrolled out-of-office blood pressure

Figure 2. Hypertension phenotype according to different office blood pressure

Fig 1.

Figure 1.Receiver operating characteristic curve analyses of office systolic (A), diastolic (B) blood pressure for identifying uncontrolled out-of-office blood pressure
Public Health Weekly Report 2021; 14: 1314-1325

Fig 2.

Figure 2.Hypertension phenotype according to different office blood pressure
Public Health Weekly Report 2021; 14: 1314-1325
Definitions of hypertension phenotypes
CharacteristicsDefinitions
Uncontrolled home BPHome BP ≥ 135/85 mmHg
Uncontrolled daytime BPABPM daytime BP ≥ 135/85 mmHg
Uncontrolled out-of-office BPDaytime BP ≥ 135/85 mmHg and/or
Home BP ≥ 135/85 mmHg
Controlled hypertensionOffice BP < target BP and
Out-of-office BP < target BP
White-coat uncontrolled hypertensionOffice BP ≥ target BP and
Out-of-office BP < target BP
Masked uncontrolled hypertensionOffice BP < target BP and
Out-of-office BP ≥ target BP
Sustained uncontrolled hypertensionOffice BP ≥ target BP and
Out-of-office BP ≥ target BP

Baseline characteristics according to status of out-of-office blood pressure
VariablesTotal
(N=468)
Controlled out-of-office BP
(N=111)
Uncontrolled out-of-office BP
(N=357)
p-value*
Age, years60.8±12.961.1±11.860.7±13.20.770
Male, N (%)270 (57.7%)62 (55.9%)208 (58.3%)0.735
Height, cm163.8±9.7163.1±10.4164.1±9.50.366
Weight, kg75.7±15.375.1±17.275.9±14.80.693
Body mass index, kg/m228.0±4.128.0±4.328.0±4.10.949
Current smoker, N (%)72 (15.4%)9 (8.1%)63 (17.6%)0.022
Alcohol drinking, N (%)283 (60.5%)66 (59.5%)217 (60.8%)0.890
Diabetes, N (%)311 (66.5%)75 (67.6%)236 (66.1%)0.865
Dyslipidemia, N (%)467 (99.8%)111 (100.0%)356 (99.7%)1.000
Chronic kidney disease, N (%)31 (6.6%)2 (1.8%)29 (8.1%)0.034
Heart failure, N (%)42 (9.0%)10 (9.0%)32 (9.0%)1.000
Myocardial infarction, N (%)21 (4.5%)6 (5.4%)15 (4.2%)0.785
Angina, N (%)102 (21.8%)30 (27.0%)72 (20.2%)0.162
Stroke, N (%)45 (9.6%)4 (3.6%)41 (11.5%)0.023
Transient ischemic attack, N (%)8 (1.7%)1 (0.9%)7 (2.0%)0.739
Blood urea nitrogen, mg/dL18.5±11.117.8±5.118.8±12.40.222
Creatinine, mg/dL0.9±0.30.9±0.21.0±0.40.001
Glucose, mg/dL117.5±31.2118.5±30.3117.2±31.50.711
Total cholesterol, mg/dL165.7±34.6164.0±38.0166.2±33.50.575
LDL-cholesterol, mg/dL89.9±32.388.7±33.190.3±32.10.669
HDL-cholesterol, mg/dL48.9±11.549.2±11.748.9±11.40.825
Triglyceride, mg/dL141.0 (105.0-191.5)142 (104.0-182.0)141 (105.0-198.5)0.642
Na+, mmol/L141.1±2.6140.6±2.5141.3±2.60.018
K+, mmol/L4.3±0.44.3±0.44.3±0.40.877
Urine albumin creatinine ratio18.5 (8.9-76.5)16.8 (8.1-42.2)20.1 (9.2-83.5)0.094

*Presented by t-test or chi-square test.


Blood pressure measurement and use of antihypertensive medications according to status of out-of-office blood pressure
VariablesTotal
(N=468)
Controlled out-of-office BP
(N=111)
Uncontrolled out-of-office BP
(N=357)
p-value*
Office SBP140.0±18.2130.6±14.2143.0±18.3<0.001
Office DBP80.0±11.776.5±10.181.1±12.0<0.001
Home SBP129.9±12.5120.1±8.5133.0±11.9<0.001
Home DBP78.9±9.274.0±6.180.4±9.5<0.001
Daytime SBP140.1±17.2122.5±7.2145.6±15.7<0.001
Daytime DBP82.6±10.574.8±5.085.1±10.6<0.001
Thiazide-like461 (98.5%)110 (99.1%)351 (98.3%)0.886
Renin-angiotensin system blocker454 (97.0%)106 (95.5%)348 (97.5%)0.452
Calcium channel blocker458 (97.9%)108 (97.3%)350 (98.0%)0.923
Beta blocker387 (82.7%)97 (87.4%)290 (81.2%)0.176
Alpha blocker37 (7.9%)5 (4.5%)32 (9.0%)0.187
Spironolactone84 (17.9%)30 (27.0%)54 (15.1%)0.007
Minoxidil2 (0.4%)0 (0.0%)2 (0.6%)1.000
Number of medications0.144
368 (14.5%)8 (7.2%)60 (16.8%)
4327 (69.9%)85 (76.6%)242 (67.8%)
562 (13.2%)15 (13.5%)47 (13.2%)
610 (2.1%)3 (2.7%)7 (2.0%)
71 (0.2%)0 (0.0%)1 (0.3%)

*Presented by t-test or chi-square test.


Cross-tabulation of office blood pressure threshold of 140/90 mmHg and out-of-office blood pressure threshold of 135/85 mmHg
Out-of-office blood pressure
ControlledUncontrolledSubtotal
Office blood pressureControlled79151230
Uncontrolled32206238
Subtotal111357468
Sensitivity71.2%
Specificity57.7%
Accuracy60.9%
Positive predictive value34.3%
Negative predictive value86.6%

Cross-tabulation of office blood pressure threshold of 130/80 mmHg and out-of-office blood pressure threshold of 135/85 mmHg
Out-of-office blood pressure
ControlledUncontrolledSubtotal
Office blood pressureControlled445498
Uncontrolled67303370
Subtotal111357468
Sensitivity39.6%
Specificity84.9%
Accuracy74.1%
Positive predictive value44.9%
Negative predictive value81.9%

Reclassification tables for uncontrolled out-of-office blood pressure according to change of office blood pressure threshold from 140/90 mmHg to 130/80 mmHg
Out-of-office blood pressureOffice blood pressure
140/90 mmHg
Office blood pressure
130/80 mmHg
Reclassification improvement
Controlled (N=111)Controlled (N=79)aControlled (N=44)-0.152i
Uncontrolled (N=35)e
Uncontrolled (N=32)bControlled (N=0)f
Uncontrolled (N=32)
Uncontrolled (N=357)Controlled (N=151)cControlled (N=54)0.407j
Uncontrolled (N=97)g
Uncontrolled (N=206)dControlled (N=0)h
Uncontrolled (N=206)

i=(f-e)/(a+c); j=(g-h)/(b+d); Net reclassification improvement = i+j = 0.255..


References

  1. Carey RM, Calhoun DA, Bakris GL, et al. Resistant hypertension: detection, evaluation, and management: a scientific statement From the American Heart Association. Hypertension 2018;72(5):e53-e90.
  2. Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension 2019;73(2):424-431.
    Pubmed KoreaMed CrossRef
  3. Sim JJ, Bhandari SK, Shi J, et al. Comparative risk of renal, cardiovascular, and mortality outcomes in controlled, uncontrolled resistant, and nonresistant hypertension. Kidney Int 2015;88(3):622-632.
    Pubmed KoreaMed CrossRef
  4. de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011;57(5):898-902.
    Pubmed CrossRef
  5. Cardoso CRL, Salles GC, Salles GF. Prognostic importance of on-treatment clinic and ambulatory blood pressures in resistant hypertension: a cohort study. Hypertension 2020;75(5):1184-1194.
    Pubmed CrossRef
  6. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008;51(6):1403-1419.
    Pubmed CrossRef
  7. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2018;71(19):e127-e248.
    CrossRef

Share

  • line

Related articles

PHWR